Is Exousia Pro Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Exousia Pro Inc (MAJI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Exousia Pro Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Exousia Pro Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Exousia Pro Inc?

Muslim investors may consider investing in Exousia Pro Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Exousia Pro Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Exousia Pro Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Exousia Pro Inc updated?

The Shariah compliance status of Exousia Pro Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Exousia Pro Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Exousia Pro Inc?

You can check the latest Shariah compliance status of Exousia Pro Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Exousia Pro Inc. Stock Analysis MAJI

United States Health Care Nano Cap

Marijuana, Inc. operates as a shell company seeking to merge with another entity with experienced management and opportunities for growth. The company is headquartered in Saint Petersburg, Florida. The company went IPO on 2010-12-28. The firm's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The firm's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).

Key Statistics of Exousia Pro Inc (MAJI)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.01$0.01

Today's Open

$0.01

Volume

1.89M

P/E Ratio (TTM)

52 Week Range

$0.01$0.21

Market Cap

585.84K

Avg. Volume

501.45K

Dividend Yield

Financial Metrics & Statements of Exousia Pro Inc (MAJI)

FAQ's for Exousia Pro Inc (MAJI)

According to Musaffa’s Shariah screening methodology, Exousia Pro Inc (MAJI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.